D
Divaya Bhutani
High Impact
Researcher
UAMS
faculty
25 h-index
183 pubs
2,661 cited
Research Areas
Links
Is this your profile? Verify and claim your profile
Biography and Research Information
Metrics
- h-index: 25
- Publications: 183
- Citations: 2,661
Selected Publications
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2025) DOI
Collaboration Network
Top Collaborators
Suzanne Lentzsch
Amyloidosis Foundation (US)
38 shared publications
- Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
Showing 5 of 38 shared publications
Rajshekhar Chakraborty
Amyloidosis Foundation (US)
33 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- How do we manage t(11;14) plasma cell disorders with venetoclax?
Showing 5 of 33 shared publications
Markus Y. Mapara
Columbia University Irving Medical Center (US)
16 shared publications
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- Reduced early mortality with <scp>Daratumumab‐based</scp> frontline therapy in <scp>AL</scp> amyloidosis: A retrospective cohort study
- Dual targeting of protein translation and nuclear protein export results in enhanced antimyeloma effects
- Cardiopulmonary exercise testing in patients with Cardiac Amyloidosis
Showing 5 of 16 shared publications
Jai Radhakrishnan
Columbia University Irving Medical Center (US)
11 shared publications
- Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis
- First report of outcomes in patients with stage I<scp>IIb AL</scp> amyloidosis treated with <scp>Dara–VCD</scp> front‐line therapy
- Reduced early mortality with <scp>Daratumumab‐based</scp> frontline therapy in <scp>AL</scp> amyloidosis: A retrospective cohort study
- Safety and Efficacy of SGLT2 Inhibitors for Amyloid Light-Chain Cardiomyopathy
- Impact of bone marrow minimal residual disease status on quality of organ response in systemic <scp>AL</scp> amyloidosis
Showing 5 of 11 shared publications
Binod Dhakal
Medical College of Wisconsin (US)
10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
10 shared publications
In database
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
Anita D’Souza
Medical College of Wisconsin (US)
10 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 10 shared publications
Meera Mohan
Medical College of Wisconsin (US)
9 shared publications
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
Showing 5 of 9 shared publications